Efficacy and Safety Study of SLC022 in Treating Pain Associated With Post Herpetic Neuralgia

ClinicalTrials.gov ID: NCT00813826

Public ClinicalTrials.gov record NCT00813826. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Oct 30, 2026, 11:19 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study Evaluating the Efficacy and Tolerability of Oral SLC022 300 mg TID, a Glial Cell Modulating Agent, Versus Placebo in the Treatment of Post Herpetic Neuralgia

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The purpose of this study is to evaluate the efficacy and safety of SLC022 in treating pain associated with post-herpetic neuralgia (PHN) in recently diagnosed patients.

Study identification

NCT ID: NCT00813826
Recruitment status: Not listed
Study type: Interventional
Phase: Phase 2
Lead sponsor: Solace Pharmaceuticals; Industry
Enrollment: 204 participants

Conditions and interventions

Conditions

Postherpetic Neuralgia

Interventions

SLC022 Drug
Placebo Drug

Drug

Eligibility (public fields only)

Age range: 18 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Jan 2009 (Type not available)
Primary completion: Oct 2009 (Estimated)
Completion: Nov 2009 (Estimated)
Last update posted: Jul 30, 2009

2009

United States locations

U.S. sites: 19
U.S. states: 14
U.S. cities: 19

Facility	City	State	ZIP	Site status
Not listed	Sierra Vista	Arizona	85635	—
Not listed	Mission Viejo	California	92691	—
Not listed	Orlando	Florida	32806	—
Not listed	Plantation	Florida	33324	—
Not listed	Marietta	Georgia	30060	—
Not listed	Oak Brook	Illinois	60523	—
Not listed	Shreveport	Louisiana	71030	—
Not listed	Brockton	Massachusetts	20301	—
Not listed	Omaha	Nebraska	68134	—
Not listed	Rochester	New York	14618	—
Not listed	Winston-Salem	North Carolina	27103	—
Not listed	Kettering	Ohio	45429	—
Not listed	Altoona	Pennsylvania	16602	—
Not listed	Philadelphia	Pennsylvania	19139	—
Not listed	West Reading	Pennsylvania	19611	—
Not listed	Dallas	Texas	75230	—
Not listed	Houston	Texas	77074	—
Not listed	San Antonio	Texas	78229	—
Not listed	Midvale	Utah	84047	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT00813826, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Jul 30, 2009 · Synced Oct 30, 2026

Open the official record

The complete public registry record, listed eligibility criteria, and available contact information for NCT00813826 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →